

Special Issue

Liquid Biopsy in Lung Cancer: Innovations in Precision Oncology

Message from the Guest Editors

Liquid biopsy allows for the detection of specific mutations in circulating tumor DNA (ctDNA), such as those in the EGFR, ALK, and KRAS genes. This information is crucial for selecting targeted therapies. For patients where tissue biopsies are difficult or risky, liquid biopsy provides a less invasive solution for obtaining diagnostic information. It can aid in detecting the presence of metastases and evaluating tumor heterogeneity, offering a more comprehensive view of the disease. Liquid biopsy plays a role in lung cancer; it can be used in early diagnosis and screening for monitoring high-risk populations, allowing for the early detection of lung tumors before obvious symptoms develop. As technology advances, it will be possible to identify more mutations and biomarkers, enhancing the personalization of treatments and therapeutic effectiveness. The increasing availability of liquid biopsy could make procedures more accessible and lower the risks associated with invasive biopsies. Therefore, you are invited to submit original articles or comprehensive reviews to this Special Issue, where we aim to open up an interesting window into the future.

Guest Editors

Dr. Maria Paola Belfiore


Section of Radiology and Radiotherapy, Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy

Dr. Valerio Nardone

Department of Precision Medicine, University of Campania "L. Vanvitelli", 80131 Naples, Italy

Deadline for manuscript submissions

closed (20 November 2025)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/232497

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).